BCLI צמיחה צפויה ברווח נקי למניה השנה brainstorm-cell.com

Brainstorm Cell (BCLI) is developing the unique NurOwn therapy, utilizing a patient's own stem cells to combat ALS. The firm's financial stability relies on external investments and grants, as it currently generates no operating income. Development is proceeding through partnerships with funds without mergers. The annual net income per share chart visualizes these processes, where the 30.50 level indicates the state of the parameter.

This metric measures the year-over-year dynamics of earnings per share, smoothing out time gaps between quarterly reports to assess the actual efficiency of the business. By analyzing the annual EPS growth trajectory, an investor separates market volatility from fundamental profitability trends. For Brainstorm Cell (BCLI), this metric is critical, as geopolitical isolation and logistical collapse are hindering international research, directly impacting the financial result.